Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

TFF Pharmaceuticals, Inc. (TFFP)

0.945   -0.005 (-0.52%) 01-27 15:18
Open: 0.9189 Pre. Close: 0.9499
High: 0.96 Low: 0.911
Volume: 59,247 Market Cap: 34(M)

Technical analysis

as of: 2023-01-27 4:48:29 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.17     One year: 1.31
Support: Support1: 0.81    Support2: 0.67
Resistance: Resistance1: 1    Resistance2: 1.12
Pivot: 1
Moving Average: MA(5): 0.94     MA(20): 1
MA(100): 2.34     MA(250): 4.39
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 20     %D(3): 22.1
RSI: RSI(14): 40.2
52-week: High: 7.69  Low: 0.81
Average Vol(K): 3-Month: 269 (K)  10-Days: 94 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TFFP ] has closed above bottom band by 25.7%. Bollinger Bands are 77.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.96 - 0.97 0.97 - 0.97
Low: 0.9 - 0.9 0.9 - 0.91
Close: 0.93 - 0.95 0.95 - 0.96

Company Description

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

Headline News

Tue, 24 Jan 2023
Demerara Bank loans St. Vincent Gov't funds to buy prefab homes ... - News Room Guyana

Mon, 23 Jan 2023
Billionaire Niel's NJJ Projet to challenge M6 and TF1 for French TNT ... -

Mon, 09 Jan 2023
TFF Pharmaceuticals (TFFP) Appoints Zamaneh Mikhak as Chief ... -

Mon, 09 Jan 2023
France stocks higher at close of trade; CAC 40 up 0.68% By ... -

Mon, 05 Dec 2022
TFF Pharmaceuticals Chief Executive Glenn Mattes Resigns >TFFP - MarketWatch

Tue, 22 Nov 2022
TFF Pharmaceuticals (TFFP) Stock: Undefeatable To Speculative - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 36 (M)
% Held by Insiders 2.229e+007 (%)
% Held by Institutions 18.3 (%)
Shares Short 735 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.417e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -17
Return on Assets (ttm) 696.7
Return on Equity (ttm) -62.1
Qtrly Rev. Growth 195020
Gross Profit (p.s.) 59.68
Sales Per Share -83.14
EBITDA (p.s.) -1.68333e+007
Qtrly Earnings Growth -1.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -31 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 1.67

Stock Dividends

Dividend 0
Forward Dividend 698480
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.